Loading...
XNASDOMH
Market cap7mUSD
Dec 27, Last price  
1.15USD
1D
-7.26%
1Q
-37.33%
Name

Dominari Holdings Inc

Chart & Performance

D1W1MN
XNAS:DOMH chart
P/E
—
P/S
3.57
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
115.86%
Rev. gr., 5y
135.75%
Revenues
2m
22,348,41823,045,65724,838,174154,6981,025,9611,359,1101,432,452820,92519,92227,00010,00033,000877,0001,236,00028,0009,0000002,039,000
Net income
-23m
L-40.67%
-2,822,046-2,848,7483,512,881-938,374-4,135,534-9,148,631-7,736,242-3,461,640-3,857,024-17,965,000-30,532,000-51,465,000-6,476,000-3,306,0001,727,000-4,183,000-12,337,000-6,919,000-38,568,000-22,882,000
CFO
-22m
L+109.80%
-385,902-525,7406,657,657-8,628,614-6,409,255-7,832,625-8,693,195-4,359,660-3,815,687-5,270,000-9,516,000-4,620,00070,000-3,272,000-2,729,000-3,017,000-4,021,000-6,603,000-10,597,000-22,232,000
Earnings
Mar 31, 2025

Profile

AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.
URL
https://aikidopharma.com/
IPO date
Mar 18, 1980
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
2,039
 
Cost of revenue
23,841
14,158
9,441
Unusual Expense (Income)
NOPBT
(21,802)
(14,158)
(9,441)
NOPBT Margin
Operating Taxes
16,461
(252)
Tax Rate
NOPAT
(21,802)
(30,619)
(9,189)
Net income
(22,882)
-40.67%
(38,568)
457.42%
(6,919)
-43.92%
Dividends
Dividend yield
Proceeds from repurchase of equity
(939)
14,833
78,219
BB yield
6.93%
-84.78%
Debt
Debt current
842
82
Long-term debt
6,477
1,442
Deferred revenue
Other long-term liabilities
Net debt
(33,211)
(63,896)
(88,727)
Cash flow
Cash from operating activities
(22,232)
(10,597)
(6,603)
CAPEX
(427)
(1,833)
(617)
Cash from investing activities
(7,170)
(14,598)
(8,853)
Cash from financing activities
(939)
(7,193)
78,303
FCF
(29,348)
(27,604)
(19,755)
Balance
Cash
16,380
42,317
79,262
Long term investments
24,150
23,103
9,465
Excess cash
40,428
65,420
88,727
Stockholders' equity
(208,763)
(185,881)
(163,765)
Invested Capital
265,977
260,410
265,360
ROIC
ROCE
EV
Common stock shares outstanding
5,229
5,334
4,847
Price
2.59
-21.04%
3.28
 
Market cap
13,544
-22.59%
17,496
 
EV
(19,667)
(46,400)
EBITDA
(21,360)
(14,346)
(9,441)
EV/EBITDA
0.92
3.23
Interest
7,761
Interest/NOPBT